Vetigenics is a clinical-stage biopharmaceutical company advancing targeted antibody therapies for pets. Co-founded by Nicola Mason, BVetMed, PhD, DACVIM, MRCVS, Professor of Medicine & Pathobiology in the Penn School of Veterinary Medicine, Don Siegel, PhD, MD, Professor of Pathology & Laboratory Medicine at Penn Medicine, and Adriann Sax, President and CEO, Vetigenics leverages a state-of-the-art phage display platform to rapidly produce canine antibodies for therapeutic purposes. In November 2023, Vetigenics announced that the first client-owned canine patient with oral melanoma received the first dose of the company’s anti-CTLA4 monoclonal antibody (VGS-001) in a clinical trial. The company recently opened a second clinical trial to determine the effects of Vetigenics‘ second fully canine checkpoint inhibitor, anti-canine PD1 (VGS-002), in dogs with bladder cancer. Read more about Vetigenics and their clinical trials to treat cancer in pets here.